Incidencia y factores asociados con las reacciones adversas tras la primera dosis de la vacuna Pfizer-BioNTech en trabajadores de la salud.

OBJECTIVE: To determine the incidence of adverse reactions (AR) after the first dose of Pfizer-BioNTech vaccine, and to identify some factors associated with AR. METHOD: A retrospective cohort study was conducted. Data were obtained through an epidemiological survey answered online. Multivariate analyses were performed to identify factors associated with early (< 2 h) and late (≥ 2 h) AR. RESULTS: A total of 2295 health care workers were included; in them, the cumulative incidence of AR was 18.2% (95% confidence interval: 16.6-19.8), where the majority were late (78.2%). The associated factors that increased the risk of early AR were being female (odds ratio [OR]: 2.23, p = 0.002) and belonging to the medical staff (OR: 1.56; p = 0.041). In late AR were being female (OR: 1.94; p < 0.0001); on the other hand, diabetes (OR: 0.46; p = 0.021), asthma (OR: 0.53; p = 0.040) and smoking (OR: 0.44, p = 0.002) were inversely associated factors. Interestingly, history of COVID-19 was not associated with either early or late AR. CONCLUSIONS: The risk of presenting some type of AR due to the Pfizer-BioNTech vaccine in health care workers is < 20%.

OBJETIVO: Determinar la incidencia de reacciones adversas (RA) tras la primera dosis de la vacuna Pfizer-BioNTech e identificar algunos factores asociados con ellas. MÉTODO: Se realizó un estudio de cohorte retrospectiva. Los datos fueron obtenidos mediante una encuesta epidemiológica contestada en línea. Se realizaron análisis multivariados para identificar factores asociados con las RA tempranas (< 2 h) y tardías (≥ 2 h). RESULTADOS: Se incluyeron 2295 trabajadores de la salud; en ellos, la incidencia acumulada de RA fue del 18.2% (intervalo de confianza del 95%: 16.6-19.8%) y la mayoría fueron tardías (78.2%). Las RA tempranas más frecuentes fueron dolor local, cefalea y mareo; en las tardías fueron dolor local, cefalea y fatiga. No se documentaron casos de anafilaxia; sin embargo, en el grupo de RA tempranas y tardías hubo un caso y tres casos, respectivamente, con síntomas sistémicos que afectaron a dos órganos diferentes. Los factores asociados que incrementaron el riesgo de RA tempranas fueron ser mujer (odds ratio [OR]: 2.23; p = 0.002) y pertenecer al personal médico (OR: 1.56; p = 0.041). En las RA tardías fue ser mujer (OR: 1.94; p < 0.0001); por su parte, la diabetes (OR: 0.46; p = 0.021), el asma (OR: 0.53; p = 0.040) y el tabaquismo (OR: 0.44; p = 0.002) fueron factores asociados inversamente. Es interesante que la historia de COVID-19 no se asoció con RA tempranas ni tardías. CONCLUSIONES: El riesgo de presentar algún tipo de RA debido a la vacuna Pfizer-BioNTech en trabajadores de la salud es < 20%.

Asthma and COVID-19 among healthcare workers from a Mexican Hospital: is there an association?

Background: Asthma does not appear to be a risk factor for developing COVID-19. Objective: The objective of the study was to analyze the role of asthma as a factor associated with COVID-19 among healthcare workers (HW). Methods: A crosssectional study was conducted in HW from a Mexican hospital. Data were obtained through an epidemiological survey that included age, sex, and history of COVID-19. Multivariate logistic regression analysis was performed to identify factors associated with COVID-19. Results: In total, 2295 HW were included (63.1% women; mean age 39.1 years); and 1550 (67.5%) were medical personnel. The prevalence of asthma in HW with COVID-19 was 8.3%; for the group without COVID-19, the prevalence was 5.3% (p = 0.011). The multivariate analyses suggested that asthma was associated with COVID-19 (OR 1.59, p = 0.007). Conclusion: Our study suggests that asthma could be a factor associated with COVID-19 in HW.

[Association of comorbidities and symptomatic infection and multisystemic inflammatory syndrome due to SARS-CoV-2 in children]. / Asociación de comorbilidades con infección sintomática y síndrome inflamatorio multisistémico por SARS-CoV-2 en niños.

BACKGROUND: In children, infection by the new coronavirus (SARS-CoV-2) usually occurs asymptomatic or with mild clinical data, only a minor proportion have severe symptoms or a set of post-infectious signs and symptoms described as Pediatric Inflammatory Multisystemic Syndrome (PIMS). AIM: To describe the association of comorbidities with symptomatic infection and PIMS due to SARS-CoV-2 in children. METHODS: Analytical cross-sectional study, pediatric patients hospitalized were included. Active infection was diagnosed by polymerase chain reaction and/or antigenic tests. Patients with PIMS were identified by the definition proposed by the World Health Organization. RESULTS: 375 patients were studied, the median age was 3.8 years. 47.7% (n: 179) had comorbidities, the most frequent were: solid neoplasms and/or hematological diseases 17.1% (n: 64), obesity 13.3% (n: 48) and chronic pneumopathies 9, 3% (n: 35). SARS-CoV-2 infection was present in 16.5% (n: 62/375) and PIMS in 10.4% (n. 39/375). Children with obesity showed a higher risk of infection (OR 2.21, 95% CI 1.05-4.6) and in those with cancer (OR 0.15, 95% CI 0.03-0.68) the PIMS risk was lower. CONCLUSIONS: The presence of comorbidities modifies the risk of infection by SARS-CoV-2 and PIMS.

SARS-CoV-2 infection among Mexican healthcare workers.

Dear editor: Healthcare workers (HCW) have been the first-line defense against pandemic SARS-CoV-2 infection, for this reason, they are highly exposed and possibly have the greatest risk of contagion...

Expresión de infección por SARS-CoV-2 en niños: infección aguda sintomática y síndrome inflamatorio multisistémico.

No disponible.